September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Long-term clinical outcomes after intravitreal bevacizumab injections or photodynamic therapy for myopic choroidal neovascularization: 7 years follow-up
Author Affiliations & Notes
  • Eui Chun Kang
    Department of Ophthalmology, Institute of Vision Research, Seoul, Korea (the Republic of)
  • Minkyo Kim
    Department of Ophthalmology, Institute of Vision Research, Seoul, Korea (the Republic of)
  • Kyou Ho Lee
    Department of Ophthalmology, Institute of Vision Research, Seoul, Korea (the Republic of)
  • Hyoung Jun Koh
    Department of Ophthalmology, Institute of Vision Research, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Eui Chun Kang, None; Minkyo Kim, None; Kyou Ho Lee, None; Hyoung Jun Koh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4444. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Eui Chun Kang, Minkyo Kim, Kyou Ho Lee, Hyoung Jun Koh; Long-term clinical outcomes after intravitreal bevacizumab injections or photodynamic therapy for myopic choroidal neovascularization: 7 years follow-up. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4444.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the long-term clinical outcomes after intravitreal bevacizumab (IVB) injections or photodynamic therapy (PDT) for myopic choroidal neovascularization (CNV) through 7 years follow-up.

Methods : In this retrospective comparative case series, a total of 37 eyes with 37 patients which were treated with IVB (17 eyes) or PDT (20 eyes) were included. Preoperative classification for myopic maculopathy was made according to the international photographic classification. The primary outcome was the mean change of best-corrected visual acuity (BCVA) between two groups from the baseline through 7 years follow-up.

Results : The mean change of BCVA from baseline to 7 years follow-up was greater in the IVB group compared with the PDT group (-0.177±0.316 vs. 0.091±0.417 logMAR, P = 0.044). The BCVA from baseline through 7 years follow-up improved in the IVB group (0.642 ± 0.427 vs. 0.463 ± 0.439 logMAR, P = 0.029), but did not improve in the PDT group (0.645 ± 0.402 vs. 0.736 ± 0.576 logMAR, P = 0.266). In subgroup-analysis with 18 eyes with preoperative tessellated fundus only (category 1), there was no difference in improvement of BCVA (-0.338 ± 0.277 vs. -0.156 ± 0.184 logMAR, P = 0.166) and progression of CRA (0.17 ± 0.47 vs. 0 mm2, P = 0.264), CSFT (250.3±14.6 vs. 247.8±38.8 µm, P = 0.929) and SFCT (140.6±74.8 vs. 146.3±104.9 µm, P = 0.929) between two groups at 7 years follow-up. However, 17 eyes with preoperative diffuse CRA (category 2) showed no change of BCVA in IVB group, but decreased BCVA in PDT group (-0.033 ± 0.289 vs. 0.338 ± 0.105 logMAR, P = 0.03). Although, the CSFT was not different between groups (237.7 ± 61.6 vs. 197.8 ± 55.4 µm, P = 0.171), the progression of CRA (1.88 ± 2.89 vs. 6.43 ± 4.44 mm2, P = 0.019) and thinned SCFT (44.3 ± 38.2 vs. 16.9 ± 16.3 µm, P = 0.028) was less in IVB group compared with PDT group.

Conclusions : The mean change of BCVA was superior in eyes treated with IVB compared to PDT for 7 years follow-up. Additionally, the decreased BCVA and the progression of CRA after PDT treatment were more prominent in eyes with preoperative diffuse CRA (category 2) compared with IVB injections.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×